Filter articles using the following links

GenSight Biologics to Attend Upcoming Investor Conferences

43rd NANOS Annual Meeting, Washington, DC (US)

GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS

GenSight Biologics Reports Full Year 2016 Financial Results

GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa

JP Morgan 35th Annual Healthcare Conference, San Francisco (CA), USA

Oddo 20th Forum – Lyon, France

GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Cell Therapy Manufacturing & Gene Therapy, Amsterdam